Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE
dc.contributor.author | Zeissler, M | |
dc.contributor.author | Eastwood, J | |
dc.contributor.author | Oliver Hanemann, C | |
dc.contributor.author | Zajicek, J | |
dc.contributor.author | Carroll, C | |
dc.date.accessioned | 2015-07-29T09:19:58Z | |
dc.date.available | 2015-07-29T09:19:58Z | |
dc.date.issued | 2013-11 | |
dc.identifier.issn | 0022-3050 | |
dc.identifier.issn | 1468-330X | |
dc.identifier.uri | http://hdl.handle.net/10026.1/3482 | |
dc.description.abstract |
Cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC) are neuroprotective in animal and cell culture models of Parkinson's disease (PD). In a PD cell culture model we recently demonstrated that Δ9-THC is neuroprotective through activation of the nuclear receptor peroxisomal proliferator-activated receptor γ (PPARγ). Furthermore, activation by specific agonists rosiglitazone and pioglitazone, has also been found neuroprotective. PPARγ is a nuclear receptor whose activation can lead to the expression of proteins involved in the de novo synthesis of mitochondria. One such protein is the PPARγ co-activator 1 α (PGC1α) as it co-activates NRF-1 mediated gene expression which is essential for the production of nuclear encoded, mitochondrial proteins. Here we investigate the effect of Δ9-THC and pioglitazone on mitochondrial biogenesis. | |
dc.format.extent | e2.58-e2 | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | BMJ | |
dc.subject | PARKINSON'S DISEASE | |
dc.subject | STROKE | |
dc.title | Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE | |
dc.type | journal-article | |
dc.type | Meeting Abstract | |
plymouth.author-url | http://www.ncbi.nlm.nih.gov/pubmed/24108924 | |
plymouth.issue | 11 | |
plymouth.volume | 84 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Neurology, Neurosurgery & Psychiatry | |
dc.identifier.doi | 10.1136/jnnp-2013-306573.150 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Applied Parkinson's Research | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Community and Primary Care | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dc.identifier.eissn | 1468-330X | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1136/jnnp-2013-306573.150 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Journal Article/Review |